Latest News for AYTU
Shares of Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) have received a consensus rating of "Hold" from the five brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 1 year
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.28 per share a year ago.
Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host conference…
AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AYTU.
U.S. House Trading
No House trades found for AYTU.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.